Summary
Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a biotechnology company that develops and delivers RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company's pipeline products include Atu027 and Atu111. Its Atu027 is developed for the treatment of pancreatic, head and neck cancer. Silence Therapeutics offers Atu111 for lung indications. The company also develops other products which includes PF-655 for diabetic macular edema and wet age related macular degeneration; and QPI 1002 for kidney transplantation and acute kidney injury. It has collaboration with pharmaceutical, biotechnology companies and academic research institutions. The company has presence in Berlin, Germany. Silence Therapeutics is headquartered in London, the UK.
Silence Therapeutics Plc (SLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Silence Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies 11
Silence Therapeutics Extends R&D Collaboration With AstraZeneca 13
Silence Therapeutics Extends Co-Development Agreement With AstraZeneca 14
Silence Therapeutics Expands Its Collaboration With Dainippon Sumitomo Pharma 15
Licensing Agreements 16
Silence Therapeutics Terminates Licensing Agreement With University Of Massachusetts 16
Equity Offering 17
Silence Therapeutics Raises USD59 Million in Private Placement of Shares 17
Silence Therapeutics Announces Private Placement Of Shares For US$16.8 Million 18
Silence Therapeutics Completes Private Placement Of Shares For US$29 Million 19
Silence Therapeutics Completes Private Placement Of Shares For US$8 Million 21
Silence Therapeutics Completes Rights Offering Of Shares For US$0.39 Million 22
Silence Therapeutics Completes Private Placement Of Shares For US$7 Million 24
Silence Therapeutics Announces Private Placement Of Shares For US$16 Million 26
Silence Therapeutics Completes Private Placement Of US$9 Million 27
Silence Therapeutics Completes Public Offering Of US$0.71 Million 29
Acquisition 31
Silence Therapeutics Completes Acquisition Of Intradigm 31
Silence Therapeutics Plc - Key Competitors 34
Key Employees 35
Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Silence Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Silence Therapeutics Plc, Deals By Therapy Area, 2010 to YTD 2016 8
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies 11
Silence Therapeutics Extends R&D Collaboration With AstraZeneca 13
Silence Therapeutics Extends Co-Development Agreement With AstraZeneca 14
Silence Therapeutics Expands Its Collaboration With Dainippon Sumitomo Pharma 15
Silence Therapeutics Terminates Licensing Agreement With University Of Massachusetts 16
Silence Therapeutics Raises USD59 Million in Private Placement of Shares 17
Silence Therapeutics Announces Private Placement Of Shares For US$16.8 Million 18
Silence Therapeutics Completes Private Placement Of Shares For US$29 Million 19
Silence Therapeutics Completes Private Placement Of Shares For US$8 Million 21
Silence Therapeutics Completes Rights Offering Of Shares For US$0.39 Million 22
Silence Therapeutics Completes Private Placement Of Shares For US$7 Million 24
Silence Therapeutics Announces Private Placement Of Shares For US$16 Million 26
Silence Therapeutics Completes Private Placement Of US$9 Million 27
Silence Therapeutics Completes Public Offering Of US$0.71 Million 29
Silence Therapeutics Completes Acquisition Of Intradigm 31
Silence Therapeutics Plc, Key Competitors 34
Silence Therapeutics Plc, Key Employees 35
Silence Therapeutics Plc, Subsidiaries 36
List of Figures
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Silence Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
